Anti-TNF drugs in patients with hepatitis B or C virus infection: safety and clinical management

Bibliography

• Olsen NJ, Stein CM. New drugs for rheumatoid arthritis. N Engl J Med 2004;350:2167-79
   PubMed Web of Science ®Google Scholar
• Dixon WG, Watson K, Lunt M, Rates of serious infection, including sitespecific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti–tumor necrosis factor therapy: results from the British Society for Rheumatology Biologics Register. Arthritis Rheum 2006;54:2368-76
   PubMed Web of Science ®Google Scholar
• Schreiber S, Campieri M, Colombel JF, Use of anti-tumour necrosis factor agents in inflammatory bowel disease. European guidelines for 2001 – 2003. Int J Colorectal Dis 2001;16:1-13
   PubMed Web of Science ®Google Scholar
• Lavanchy D. Worldwide epidemiology of HBV infection, disease burden, and vaccine prevention. J Clin Virol 2005;34(Suppl 1):S1-3
   PubMed Web of Science ®Google Scholar
• Lee WM. Hepatitis B virus infection. N Engl J Med 1997;337:1733-45
   PubMed Web of Science ®Google Scholar
• Raimondo G, Allain J-P, Brunetto MR, Statements from the Taormina expert meeting on occult hepatitis B virus infection. J Hepatol 2008;49:652-–657
   PubMed Web of Science ®Google Scholar
• Lok AS, McMahon BJ. Chronic hepatitis B: update 2009. Hepatology 2009;50:661-2
   PubMed Web of Science ®Google Scholar
• Hadziyannis SJ, Vassilopoulos D. Hepatitis B e antigen-negative chronic hepatitis B. Hepatology 2001;34:617-24
   PubMed Web of Science ®Google Scholar
• Raimondo G, Pollicino T, Cacciola I, Squadrito G. Occult hepatitis B infection. J Hepatol 2007;46:160-70
   PubMed Web of Science ®Google Scholar
• Marzano A, Angelucci E, Andreone P, Prophylaxis and treatment of hepatitis B in immunocompromised patients. Dig Liv Dis 2007;39:397-408
   Web of Science ®Google Scholar
• Biancone L, Pavia M, Del Vecchio Blanco G, Hepatitis B and C virus infection in Crohn's disease. Inflamm Bowel Dis 2001;7:287-94
   PubMed Web of Science ®Google Scholar
• Caporali R, Bobbio-Pallavicini F, Atzeni F, Safety of tumor necrosis factor alpha blockers in hepatitis B virus occult carriers (hepatitis B surface antigen negative/anti-hepatitis B core antigen positive) with rheumatic diseases. Arthritis Care Res 2010;62:749-54
   PubMed Web of Science ®Google Scholar
• Charpin C, Guis S, Colson P, Safety of TNF-blocking agents in rheumatic patients with serology suggesting past hepatitis B state: results from a cohort of 21 patients. Arthritis Res Ther 2009;11:R179
   PubMed Web of Science ®Google Scholar
• Chevaux JB, Nani A, Oussalah A, Prevalence of hepatitis B and C and risk factors for nonvaccination in inflammatory bowel disease patients in Northeast France. Inflamm Bowel Dis 2010;16:916-24
   PubMed Web of Science ®Google Scholar
• Loras C, Saro C, Gonzalez-Huix F, Prevalence and factors related to hepatitis B and C in inflammatory bowel disease patients in Spain: a nationwide, multicenter study. Am J Gastroenterol 2009;104:57-63
   PubMed Web of Science ®Google Scholar
• Kasahara S, Ando K, Saito K, Lack of tumor necrosis factor alpha induces impaired proliferation of hepatitis B virus-specific cytotoxic T lymphocytes. J Virol 2003;77:2469-76
   PubMed Web of Science ®Google Scholar
• Herbein G, O'Brien WA. Tumor necrosis factor (TNF)-alpha and TNF receptors in viral pathogenesis. Proc Soc Exp Biol Med 2000;223:241-57
   PubMed Web of Science ®Google Scholar
• Carroll MB, Bond ML. Use of tumor necrosis factor–alpha inhibitors in patients with chronic hepatitis B infection. Semin Arthritis Rheum 2008;38:208-17
   PubMed Web of Science ®Google Scholar
• Guidotti LG, Ishikawa T, Hobbs MV, Intracellular inactivation of the hepatitis B virus by cytotoxic T lymphocytes. Immunity 1996;4:25-36
   PubMed Web of Science ®Google Scholar
• Ozorio G, McGarity B, Bak H, Autoimmune hepatitis following infliximab therapy for ankylosing spondylitis. Med J Aust 2007;187:524-6
   PubMed Web of Science ®Google Scholar
• Garcıa Aparicio AM, Rey JR, Sanz AH, Alvarez JS. Successful treatment with etanercept in a patient with hepatotoxicity closely related to infliximab. Clin Rheumatol 2007;26:811-13
   PubMed Web of Science ®Google Scholar
• Thiefin G, Morelet A, Heurgue A, Infliximab-induced hepatitis: absence of cross-toxicity with etanercept. Joint Bone Spine 2008;15:737-9
   Web of Science ®Google Scholar
• Calabrese LH, Zein NN, Vassilopoulos D. Hepatitis B virus (HBV) reactivation with immunosuppressive therapy in rheumatic diseases: assessment and preventive strategies. Ann Rheum Dis 2006;65:983-9
   PubMed Web of Science ®Google Scholar
• Ueno Y, Tanaka S, Shimamoto M, Infliximab therapy for Crohn's disease in a patient with chronic hepatitis B. Dig Dis Sci 2005;50:163-6
   PubMed Web of Science ®Google Scholar
• Colbert C, Chavarria A, Berkelhammer C. Fulminant hepatic failure in chronic hepatitis B on withdrawal of corticosteroids, azathioprine and infliximab for Crohn's disease. Inflamm Bowel Dis 2007;13:1453-4
   PubMed Web of Science ®Google Scholar
• Ojiro K, Naganuma M, Ebinuma H, Reactivation of hepatitis B in a patient with Crohn's disease treated using infliximab. J Gastroenterol 2008;43:397-401
   PubMed Web of Science ®Google Scholar
• Millonig G, Kern M, Ludwiczek O, Subfulminant hepatitis B after infliximab in Crohn's disease: need for HBV-screening? World J Gastroenterol 2006;12:974-6
   PubMed Web of Science ®Google Scholar
• Esteve M, Saro C, Gonzalez-Huix F, Chronic hepatitis B reactivation following infliximab therapy in Crohn's disease patients: need for primary prophylaxis. Gut 2004;53:1363-5
   PubMed Web of Science ®Google Scholar
• Del Valle Garcia-Sanchez M, Gomez-Camacho F, Poyato-Gonzalez A, Infliximab therapy in a patient with Crohn's disease and chronic hepatitis B virus infection. Inflamm Bowel Dis 2004;10:701-2
   PubMed Web of Science ®Google Scholar
• Wendling D, Di Martino V, Prati C, Spondyloarthropathy and chronic B hepatitis. Effect of anti-TNF therapy. Joint Bone Spine 2009;76:308-11
   PubMed Web of Science ®Google Scholar
• Wendling D, Auge B, Bettinger D, Reactivation of a latent precore mutant hepatitis B virus related chronic hepatitis during infliximab treatment for severe spondyloarthropathy. Ann Rheum Dis 2005;64:788-9
   PubMed Web of Science ®Google Scholar
• Garcia-Vidal C, Rodriguez-Fernandez S, Teijon S, Risk factors for opportunistic infections in infliximab-treated patients: the importance of screening in prevention. Eur J Clin Microbiol Infect Dis 2009;28:331-7
   PubMed Web of Science ®Google Scholar
• Cansu DU, Kalifoglu T, Korkmaz C. Short-term course of chronic hepatitis B and C under treatment with etanercept associated different disease modifying antirheumatic drugs without antiviral prophylaxis. J Rheumatol 2008;35:421-4
   PubMed Web of Science ®Google Scholar
• Ostuni P, Botsios C, Punzi L, Hepatitis B reactivation in a chronic hepatitis B surface antigen carrier with rheumatoid arthritis treated with infliximab and low dose methotrexate. Ann Rheum Dis 2003;62:686-7
   PubMed Web of Science ®Google Scholar
• Sakellariou GT, Chatzigiannis I. Long-term anti-TNF therapy for ankylosing spondylitis in two patients with chronic HBV infection. Clin Rheumatol 2007;26:950-2
   PubMed Web of Science ®Google Scholar
• Li S, Kaur PP, Chan V, Berney S. Use of tumor necrosis factor-alpha (TNF-alpha) antagonists infliximab, etanercept and adalimumab in patients with concurrent rheumatoid arthritis and hepatitis B or hepatitis C: a retrospective record review of 11 patients. Clin Rheumatol 2009;28:787-91
   PubMed Web of Science ®Google Scholar
• Kaur PP, Chan VC, Berney SN. Histological evaluation of liver in two rheumatoid arthritis patients with chronic hepatitis B and C treated with TNF-alpha blockade: case reports. Clin Rheumatol 2008;27:1069-71
   PubMed Web of Science ®Google Scholar
• Michel M, Duvoux C, Hezode C, Cherqui D. Fulminant hepatitis after infliximab in a patient with hepatitis B virus treated for an adult onset Still's disease. J Rheumatol 2003;30:1624-5
   PubMed Web of Science ®Google Scholar
• Robinson H, Walker-Bone K. Anti-TNF-alpha therapy for rheumatoid arthritis among patients with chronic hepatitis B infection. Rheumatology 2009;48:450-1
   PubMedGoogle Scholar
• Anelli MG, Torres DD, Manno C, Improvement of renal function and disappearance of hepatitis B virus DNA in a patient with rheumatoid arthritis and renal amyloidosis following treatment with infliximab. Arthritis Rheum 2005;52:2519-20
   PubMed Web of Science ®Google Scholar
• Kuwabara H, Fukuda A, Tsuda Y, Shibayama Y. Precore mutant hepatitis B virus-associated fulminant hepatitis during infliximab therapy for rheumatoid arthritis. Clin Rheumatol 2010; published online 9 April 2010; doi: 10.1007/s10067-010-1438-y.
   PubMedGoogle Scholar
• Verhelst X, Orlent H, Colle I, Subfulminant hepatitis B during treatment with adalimumab in a patient with rheumatoid arthritis and chronic hepatitis B. Eur J Gastroenterol Hepatol 2010;22:494-9
   PubMed Web of Science ®Google Scholar
• Chung SJ, Kim JK, Park MC, Reactivation of hepatitis B viral infection in inactive HBsAg carriers following anti-tumor necrosis factor-alpha therapy. J Rheumatol 2009;36:2416-20
   PubMed Web of Science ®Google Scholar
• Montiel PM, Solis JA, Chirinos JA, Hepatitis B virus reactivation during therapy with etanercept in an HBsAg-negative and anti-HBs-positive patient. Liver Int 2008;28:718-20
   PubMed Web of Science ®Google Scholar
• Madonia S, Orlando A, Scimeca D, Occult hepatitis B and infliximab-induced HBV reactivation. Inflamm Bowel Dis 2007;13:508-9
   PubMed Web of Science ®Google Scholar
• Matsumoto T, Marusawa H, Dogaki M, Adalimumab-induced lethal hepatitis B virus reactivation in an HBsAg-negative patient with clinically resolved hepatitis B virus infection. Liver Int 2010;30:1241-2
   PubMed Web of Science ®Google Scholar
• Tamori A, Koike T, Goto H, Prospective study of reactivation of hepatitis B virus in patients with rheumatoid arthritis who received immunosuppressive therapy: evaluation of both HBsAg-positive and HBsAg-negative cohorts. J Gastroenterol 2011;46:556-64
   PubMed Web of Science ®Google Scholar
• Vassilopoulos D, Apostolopoulou A, Hadziyannis E, Long-term safety of anti-TNF treatment in patients with rheumatic diseases and chronic or resolved hepatitis B virus infection. Ann Rheum Dis 2010;69:1352-5
   PubMed Web of Science ®Google Scholar
• Lubel JS, Angus PW. Hepatitis B reactivation in patients receiving cytotoxic chemotherapy: diagnosis and management. J Gastroenterol Hepatol 2010;25:864-71
   PubMed Web of Science ®Google Scholar
• Lau GK, Yiu HH, Fong DY, Early is superior to deferred preemptive lamivudine therapy for hepatitis B patients undergoing chemotherapy. Gastroenterology 2003;125:1742-9
   PubMed Web of Science ®Google Scholar
• Hsu C, Hsiung CA, Su IJ, A revisit of prophylactic lamivudine for chemotherapy-associated hepatitis B reactivation in non-Hodgkin's lymphoma: a randomized trial. Hepatology 2008;47:844-53
   PubMed Web of Science ®Google Scholar
• Katz LH, Fraser A, Gafter-Gvili A, Lamivudine prevents reactivation of hepatitis B and reduces mortality in immunosuppressed patients: systematic review and meta-analysis. J Viral Hepat 2008;15:89-102
   PubMed Web of Science ®Google Scholar
• European Association For The Study Of The Liver. EASL Clinical Practice Guidelines: management of chronic hepatitis B. J Hepatol 2009;50:227-42
   PubMed Web of Science ®Google Scholar
• Ziakas PD, Karsaliakos P, Mylonakis E. Effect of prophylactic lamivudine for chemotherapy-associated hepatitis B reactivation in lymphoma: a meta-analysis of published clinical trials and a decision tree addressing prolonged prophylaxis and maintenance. Haematologica 2009;94:998-1005
   PubMed Web of Science ®Google Scholar
• Roux CH, Brocq O, Breuil V, Safety of anti-TNF-alpha therapy in rheumatoid arthritis and spondyloarthropathies with concurrent B or C chronic hepatitis. Rheumatology 2006;45:1294-7
   PubMed Web of Science ®Google Scholar
• Oniankitan O, Duvoux C, Challine D, Infliximab therapy for rheumatic diseases in patients with chronic hepatitis B or C. J Rheumatol 2004;31:107-9
   PubMed Web of Science ®Google Scholar
• Benucci M, Manfredi M, Mecocci L. Effect of etanercept plus lamivudine in a patient with rheumatoid arthritis and viral hepatitis B. J Clin Rheumatol 2008;14:245-6
   PubMed Web of Science ®Google Scholar
• Zingarelli S, Airo P, Frassi M, Prophylaxis and therapy of HBV infection in 20 patients treated with disease modifying antirheumatic drugs or with biological agents for rheumatic diseases. Reumatismo 2008;60:22-17
   PubMedGoogle Scholar
• Zoulim F. Hepatitis B virus resistance to antiviral drugs: where are we going? Liver Int 2011;31(Suppl 1):111-16
   PubMedGoogle Scholar
• Esteve M, Loras C, Gonzalez-Huix F. Lamivudine resistance and exacerbation of hepatitis B in infliximab-treated Crohn's disease patient. Inflamm Bowel Dis 2007;13:1450-1
   PubMed Web of Science ®Google Scholar
• Conde-Taboada A, Munoz JP, Munoz LC. Infliximab treatment for severe psoriasis in a patient with active hepatitis B virus infection. J Am Acad Dermatol 2009;60:1077-80
   PubMed Web of Science ®Google Scholar
• Kuroda T, Wada Y, Kobayashi D, Effect of etanercept and entecavir in a patient with rheumatoid arthritis who is a hepatitis B carrier: a review of the literature. Rheumatol Int 2010; published online 9 January 2010; doi: 10.1007/s00296-009-1344-2
   Web of Science ®Google Scholar
• Tenney DJ, Rose RE, Baldick CJ, Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naive patients is rare through 5 years of therapy. Hepatology 2009;49:1503-14
   PubMed Web of Science ®Google Scholar
• Snow-Lampart A, Chappell B, Curtis M, No resistance to tenofovir disoproxil fumarate detected after up to 144 weeks of therapy in patients monoinfected with chronic hepatitis B virus. Hepatology 2011;53:763-73
   PubMed Web of Science ®Google Scholar
• Lavanchy D. The global burden of hepatitis C. Liver Int 2009;29:74-81
   PubMed Web of Science ®Google Scholar
• Gerlach JT, Diepolder HM, Zachoval R, Acute hepatitis C: high rate of both spontaneous and treatment-induced viral clearance. Gastroenterology 2003;125:80-8
   PubMed Web of Science ®Google Scholar
• Sangiovanni A, Prati GM, Fasani P, The natural history of compensated cirrhosis due to hepatitis C virus: a 17-year cohort study of 214 patients. Hepatology 2006;43:1303-10
   PubMed Web of Science ®Google Scholar
• Marabita F, Aghemo A, De Nicola S, Genetic variation in IL28B gene is not associated with fibrosis progression in patients with chronic hepatitis C and known date of infection. Hepatology 2011;54:1127-34
   PubMed Web of Science ®Google Scholar
• EASL clinical practice guidelines: management of hepatitis C virus infection. J Hepatol 2011;55:245-64
   PubMed Web of Science ®Google Scholar
• Fraquelli M, Rigamonti C, Casazza G, Reproducibility of transient elastography in the evaluation of liver fibrosis in patients with chronic liver disease. Gut 2007;56:968-73
   PubMed Web of Science ®Google Scholar
• Zylberberg H, Rimaniol AC, Pol S, Soluble tumor necrosis factor receptors in chronic hepatitis C: a correlation with histological fibrosis and activity. J Hepatol 1999;30:185-91
   PubMed Web of Science ®Google Scholar
• Aghemo A, Rumi MG, Colombo M. Pegylated interferons alpha2a and alpha2b in the treatment of chronic hepatitis C. Nat Rev Gastroenterol Hepatol 2010;7:485-94
   PubMed Web of Science ®Google Scholar
• Vezali E, Aghemo A, Colombo M. Interferon in the treatment of chronic hepatitis C: a drug caught between past and future. Expert Opin Biol Ther 2011;11:301-13
   PubMed Web of Science ®Google Scholar
• Dill MT, Duong FH, Vogt JE, Interferon-induced gene expression is a stronger predictor of treatment response than IL28B genotype in patients with hepatitis C. Gastroenterology 2011;140:1021-31
   PubMed Web of Science ®Google Scholar
• Zein NN. Etanercept as an adjuvant to interferon and ribavirin in treatment-naive patients with chronic hepatitis C virus infection: a phase II randomized, double-blind, placebo-controlled study. J Hepatol 2005;42:315-22
   PubMed Web of Science ®Google Scholar
• Cope AP, Londei M, Chu NR, Chronic exposure to tumor necrosis factor (TNF) in vitro impairs the activation of T cells through the T cell receptor/CD3 complex: reversal in vivo by anti-TNF antibodies in patients with rheumatoid arthritis. J Clin Invest 1994;94:749-60
   PubMed Web of Science ®Google Scholar
• Gerlach JT, Diepolder HM, Jung MC, Recurrence of hepatitis C virus after loss of virus-specific CD4+ T-cell response in acute hepatitis C. Gastroenterology 1999;117:933-41
   PubMed Web of Science ®Google Scholar
• Kamal SM, Fehr J, Roesler B, Peginterferon alone or with ribavirin enhances HCV-specific CD4 T-helper 1 responses in patients with chronic hepatitis C. Gastroenterology 2002;123:1070-83
   PubMed Web of Science ®Google Scholar
• Ferri C, Ferraccioli G, Ferrari D, Safety of anti-tumor necrosis factor-alpha therapy in patients with rheumatoid arthritis and chronic hepatitis C virus infection. J Rheumatol 2008;35:1944-9
   PubMed Web of Science ®Google Scholar
• Peterson JR, Hsu FC, Simkin PA, Wener MH. Effect of tumour necrosis factor alpha antagonists on serum transaminases and viraemia in patients with rheumatoid arthritis and chronic hepatitis C infection. Ann Rheum Dis 2003;62:1078-82
   PubMed Web of Science ®Google Scholar
• Parke FA, Reveille JD. Anti-tumor necrosis factor agents for rheumatoid arthritis in the setting of chronic hepatitis C infection. Arthritis Rheum 2004;51:800-4
   PubMed Web of Science ®Google Scholar
• Bellisai F, Giannitti C, Donvito A, Galeazzi M. Combination therapy with cyclosporine A and anti-TNF-alpha agents in the treatment of rheumatoid arthritis and concomitant hepatitis C virus infection. Clin Rheumatol 2007;26:1127-9
   PubMed Web of Science ®Google Scholar
• Niewold TB, Gibofsky A. Concomitant interferon-alpha therapy and tumor necrosis factor alpha inhibition for rheumatoid arthritis and hepatitis C. Arthritis Rheum 2006;54:2335-7
   PubMed Web of Science ®Google Scholar
• Abdelmalek MF, Liu C, Valentine JF. Successful treatment of chronic hepatitis C with pegylated interferon, ribavirin, and infliximab in a patient with Crohn's disease. Am J Gastroenterol 2007;102:1333-4
   PubMed Web of Science ®Google Scholar
• Campbell S, Ghosh S. Infliximab therapy for Crohn's disease in the presence of chronic hepatitis C infection. Eur J Gastroenterol Hepatol 2001;13:191-2
   PubMed Web of Science ®Google Scholar
• Holtmann MH, Galle PR, Neurath MF. Treatment of patients with Crohn's disease and concomitant chronic hepatitis C with a chimeric monoclonal antibody to TNF. Am J Gastroenterol 2003;98:504-5
   PubMed Web of Science ®Google Scholar
• Rokhsar C, Rabhan N, Cohen SR. Etanercept monotherapy for a patient with psoriasis, psoriatic arthritis, and concomitant hepatitis C infection. J Am Acad Dermatol 2006;54:361-2
   PubMed Web of Science ®Google Scholar
• De Simone C, Paradisi A, Capizzi R, Etanercept therapy in two patients with psoriasis and concomitant hepatitis C. J Am Acad Dermatol 2006;54:1102-4
   PubMed Web of Science ®Google Scholar
• Cassano N, Vena GA. Etanercept treatment in a hemodialysis patient with severe cyclosporine-resistant psoriasis and hepatitis C virus infection. Int J Dermatol 2008;47:980-1
   PubMed Web of Science ®Google Scholar
• Alcaide AJ, Barrera MV, Habicheyn S, Safety of etanercept therapy in a patient with psoriasis, Down's syndrome and concomitant hepatitis C virus infection. J Eur Acad Dermatol Venereol 2008;22:1514-16
   PubMedGoogle Scholar
• Marotte H, Fontanges E, Bailly F, Etanercept treatment for three months is safe in patients with rheumatological manifestations associated with hepatitis C virus. Rheumatology 2007;46:97-9
   PubMed Web of Science ®Google Scholar
• Cavazzana I, Ceribelli A, Cattaneo R, Franceschini F. Treatment with etanercept in six patients with chronic hepatitis C infection and systemic autoimmune diseases. Autoimmun Rev 2008;8:104-6
   PubMed Web of Science ®Google Scholar
• Hui CK, Belaye T, Montegrande K, Wright TL. A comparison in the progression of liver fibrosis in chronic hepatitis C between persistently normal and elevated transaminase. J Hepatol 2003;38:511-17
   PubMed Web of Science ®Google Scholar
• Ierardi E, Valle ND, Nocchiero MC, Onset of liver damage after a single administration of infliximab in a patient with refractory ulcerative colitis. Clin Drug Investig 2006;26:673-6
   PubMed Web of Science ®Google Scholar
• Soto-Fernandez S, Gonzalez-Carro P, DePedro-Esteban A, Infliximab-induced hepatitis in a patient with Crohn's disease. Gastroenterol Hepatol 2006;29:320-2
   PubMedGoogle Scholar
• Wahie S, Alexandroff A, Reynolds NJ. Hepatitis: a rare, but important, complication of infliximab therapy for psoriasis. Clin Exp Dermatol 2006;31:460-1
   PubMed Web of Science ®Google Scholar
• Carlsen KM, Riis L, Madsen OR. Toxic hepatitis induced by infliximab in a patient with rheumatoid arthritis with no relapse after switching to etanercept. Clin Rheumatol 2009;28:1001-3
   PubMed Web of Science ®Google Scholar
• Kluger N, Girard C, Guillot B, Bessis D. Efficiency and safety of etanercept after acute hepatitis induced by infliximab for psoriasis. Acta Derm Venereol 2009;89:332-4
   PubMed Web of Science ®Google Scholar
• Mancini S, Amorotti E, Vecchio S, Infliximab-related hepatitis: discussion of a case and review of the literature. Intern Emerg Med 2010;5:193-200
   PubMed Web of Science ®Google Scholar
• Menghini VV, Arora AS. Infliximab-associated reversible cholestatic liver disease. Mayo Clin Proc 2001;76:84-6
   PubMed Web of Science ®Google Scholar
• Saleem G, Li SC, MacPherson BR, Cooper SM. Hepatitis with interface inflammation and IgG, IgM, and IgA anti-double-stranded DNA antibodies following infliximab therapy: comment on the article by Charles et al. Arthritis Rheum 2001;44:1966-8
   PubMed Web of Science ®Google Scholar
• Germano V, Picchianti Diamanti A, Baccano G, Autoimmune hepatitis associated with infliximab in a patient with psoriatic arthritis. Ann Rheum Dis 2005;64:1519-20
   PubMed Web of Science ®Google Scholar
• Tobon GJ, Canas C, Jaller JJ, Serious liver disease induced by infliximab. Clin Rheumatol 2007;26:578-81
   PubMed Web of Science ®Google Scholar
• Marques M, Magro F, Cardoso H, Infliximab-induced lupus-like syndrome associated with autoimmune hepatitis. Inflamm Bowel Dis 2008;14:723-5
   PubMed Web of Science ®Google Scholar
• Becker H, Willeke P, Domschke W, Gaubitz M. Etanercept tolerance in a patient with previous infliximab-induced hepatitis. Clin Rheumatol 2008;27:1597-8
   PubMed Web of Science ®Google Scholar
• Fairhurst DA, Sheehan-Dare R. Autoimmune hepatitis associated with infliximab in a patient with palmoplantar pustular psoriasis. Clin Exp Dermatol 2009;34:421-2
   PubMed Web of Science ®Google Scholar
• Coffin CS, Fraser HF, Panaccione R, Ghosh S. Liver diseases associated with anti-tumor necrosis factor-alpha (TNF-alpha) use for inflammatory bowel disease. Inflamm Bowel Dis 2011;17:479-84
   PubMed Web of Science ®Google Scholar